Laurus Labs continues to command attention on Dalal Street, with shares climbing 30% following a strong performance report for the fiscal year. Market experts maintain a bullish outlook, driven by the company’s strategic shift toward its Contract Development and Manufacturing Organization (CDMO) segment.
The company has committed a substantial capital expenditure of ₹3,000 crore to scale its infrastructure. This aggressive investment is designed to capitalize on complex chemical manufacturing and high-value research partnerships, which are expected to account for a significantly larger portion of total revenue by the end of the decade.
Key growth drivers include:
- Enhanced operating margins from an improved product portfolio.
- Expansion of high-tech production facilities to meet global demand.
- Consistent growth across diverse business units.
Brokerages have responded by upgrading earnings targets, citing the company's resilient business model. As the CDMO landscape remains competitive, investors appear confident that Laurus Labs is well-positioned to maintain its current growth trajectory through 2030.
